{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:02:48Z","timestamp":1787022168721,"version":"build-2736575974"},"reference-count":56,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:00:00Z","timestamp":1743638400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007401","name":"Sri Ramachandra University","doi-asserted-by":"publisher","award":["U02B180535"],"award-info":[{"award-number":["U02B180535"]}],"id":[{"id":"10.13039\/501100007401","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Heart failure (HF) is a growing health problem and around two percent are affected in the general population. Accurate diagnostic markers that have the potential for early diagnosis of HF are lacking. This study aimed to compare the expression levels of microRNA-210-3p with biomarkers NT-proBNP, sST2, and galectin-3, in heart failure patients with preserved and reduced ejection fractions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>The cross-sectional study was conducted on 270 hypertensive heart failure patients in the age group of 30 to 75 years of both genders. The participants with evidence of HF were recruited from the Department of Cardiology in a tertiary care hospital in Chennai, India. MicroRNA-210-3p was analyzed by qRT-PCR in a stratified sample of 80 HF patients and 20 apparently healthy individuals. Biomarkers were analyzed by ELISA. Institutional ethics committee approval and written informed consent were obtained. Statistical analysis was performed using R software (4.2.1). Based on the type of distribution of data, appropriate statistical tools were used. p-value \u2264\u2009 0.05 was considered to be statistically significant.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>All the biomarkers including microRNA-210-3p were significantly higher in HFrEF than in HFpEF. MAGGIC score showed a positive correlation with all the biomarkers. The cut-off of microRNA-210-3p was 5.03.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>All the biomarkers were significantly elevated in HFrEF compared to HFpEF. However, microRNA-210-3p could be an early marker in the diagnosis of heart failure. The strategy of employing a multi-marker approach could help in the early diagnosis as well as in stratifying the HF patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0320365","type":"journal-article","created":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T16:05:26Z","timestamp":1743696326000},"page":"e0320365","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":12,"title":["Association of microRNA-210-3p with NT-proBNP, sST2, and Galectin-3 in heart failure patients with preserved and reduced ejection fraction: A cross-sectional study"],"prefix":"10.1371","volume":"20","author":[{"given":"Jasmine Chandra","family":"Arul","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudagar Singh","family":"Raja Beem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohanalakshmi","family":"Parthasarathy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5377-7847","authenticated-orcid":true,"given":"Mahesh Kumar","family":"Kuppusamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karthikeyan","family":"Rajamani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0720-6063","authenticated-orcid":true,"given":"Santhi","family":"Silambanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,4,3]]},"reference":[{"key":"pone.0320365.ref001","doi-asserted-by":"crossref","first-page":"829151","DOI":"10.3389\/fcvm.2021.829151","article-title":"Diagnostic value of serum concentration of galectin-3 in patients with heart failure with preserved ejection fraction","volume":"8","author":"J Jiang","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"pone.0320365.ref002","doi-asserted-by":"crossref","first-page":"1","DOI":"10.21037\/amj.2020.03.03","article-title":"Global epidemiology and future trends of heart failure","volume":"5","author":"G Lippi","year":"2020","journal-title":"AME Med J"},{"key":"pone.0320365.ref003","doi-asserted-by":"crossref","first-page":"601364","DOI":"10.3389\/fcvm.2020.601364","article-title":"Biomarkers for heart failure prognosis: Proteins, genetic scores and non-coding rnAs","volume":"7","author":"A Shrivastava","year":"2020","journal-title":"Front Cardiovasc Med"},{"issue":"2","key":"pone.0320365.ref004","doi-asserted-by":"crossref","first-page":"112","DOI":"10.2174\/1573403X11309020004","article-title":"Heart failure in east asia","volume":"9","author":"Y Guo","year":"2013","journal-title":"Curr Cardiol Rev"},{"issue":"5","key":"pone.0320365.ref005","first-page":"283","article-title":"Heart failure: Epidemiology and prevention in india","volume":"23","author":"MD Huffman","year":"2010","journal-title":"Natl Med J India"},{"issue":"27","key":"pone.0320365.ref006","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: The task force for the diagnosis and treatment of acute and chronic heart failure of the european society of cardiology (ESC) developed with the special contribution of the heart failure association (HFA) of the ESC","volume":"37","author":"ESC Scientific Document Group","year":"2016","journal-title":"Eur Heart J"},{"issue":"36","key":"pone.0320365.ref007","first-page":"3599","article-title":"ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"42","author":"TA McDonagh","year":"2021","journal-title":"Eur Heart J"},{"issue":"1","key":"pone.0320365.ref008","doi-asserted-by":"crossref","first-page":"242","DOI":"10.3390\/cells9010242","article-title":"Cellular and molecular differences between hfpef and hfref: A step ahead in an improved pathological understanding","volume":"9","author":"SJ Simmonds","year":"2020","journal-title":"Cells"},{"issue":"1","key":"pone.0320365.ref009","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.gheart.2012.12.006","article-title":"The epidemiology of congestive heart failure: The framingham heart study perspective","volume":"8","author":"SS Mahmood","year":"2013","journal-title":"Glob Heart"},{"issue":"1","key":"pone.0320365.ref010","doi-asserted-by":"crossref","first-page":"7","DOI":"10.15420\/cfr.2016:25:2","article-title":"Global public health burden of heart failure","volume":"3","author":"G Savarese","year":"2017","journal-title":"Card Fail Rev"},{"issue":"2","key":"pone.0320365.ref011","first-page":"145","article-title":"Soluble ST2 testing: A promising biomarker in the management of heart failure","volume":"106","author":"H Villacorta","year":"2016","journal-title":"Arq Bras Cardiol"},{"issue":"8","key":"pone.0320365.ref012","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.3390\/biom11081167","article-title":"The role of galectin-3 and ST2 in cardiology: A short review","volume":"11","author":"A Merino-Merino","year":"2021","journal-title":"Biomolecules"},{"issue":"5","key":"pone.0320365.ref013","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.1002\/ehf2.13919","article-title":"Serum microRNAs are key predictors of long-term heart failure and cardiovascular death after myocardial infarction","volume":"9","author":"LM Rinc\u00f3n","year":"2022","journal-title":"ESC Heart Fail"},{"key":"pone.0320365.ref014","first-page":"4727283","article-title":"Effect of hypoxia-induced microRNA-210 expression on cardiovascular disease and the underlying mechanism","author":"Y Guan","year":"2019","journal-title":"Oxid Med Cell Longev"},{"issue":"3","key":"pone.0320365.ref015","doi-asserted-by":"crossref","first-page":"e0214363","DOI":"10.1371\/journal.pone.0214363","article-title":"Prognostic value of NT-proBNP added to clinical parameters to predict two-year prognosis of chronic heart failure patients with mid-range and reduced ejection fraction - A report from FAR NHL prospective registry","volume":"14","author":"J Spinar","year":"2019","journal-title":"PLoS One"},{"issue":"6","key":"pone.0320365.ref016","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.3390\/jcm11061718","article-title":"Chronic heart failure: Diagnosis and management beyond lvef classification","volume":"11","author":"F Triposkiadis","year":"2022","journal-title":"J Clin Med"},{"issue":"Supplement","key":"pone.0320365.ref017","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.4103\/0971-9784.192617","article-title":"Left ventricular global systolic function assessment by echocardiography","volume":"19","author":"S Chengode","year":"2016","journal-title":"Ann Card Anaesth"},{"issue":"29","key":"pone.0320365.ref018","doi-asserted-by":"crossref","first-page":"51","DOI":"10.54530\/jcmc.14","article-title":"Relation of waist hip ratio and body mass index with the vital capacity","volume":"9","author":"P Karmacharya","year":"2019","journal-title":"JCMC"},{"issue":"6","key":"pone.0320365.ref019","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1161\/01.HYP.0000107251.49515.c2","article-title":"Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure","volume":"42","author":"AV Chobanian","year":"2003","journal-title":"Hypertension"},{"issue":"7","key":"pone.0320365.ref020","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.2337\/dc09-9033","article-title":"International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes","volume":"32","author":"International Expert Committee","year":"2009","journal-title":"Diabetes Care"},{"issue":"10","key":"pone.0320365.ref021","doi-asserted-by":"crossref","DOI":"10.1161\/CIR.0000000000000485","article-title":"American heart association statistics committee and stroke statistics subcommittee. heart disease and stroke statistics-2017 update: A report from the american heart association","volume":"135","author":"EJ Benjamin","year":"2017","journal-title":"Circulation"},{"key":"pone.0320365.ref022","doi-asserted-by":"crossref","first-page":"ehab793","DOI":"10.1093\/eurheartj\/ehab793","article-title":"The cardiology society of india-kerala acute heart failure registry: Poor adherence to guideline-directed medical therapy","author":"S Joseph","year":"2021","journal-title":"Eur Heart J"},{"issue":"1","key":"pone.0320365.ref023","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mjafi.2019.12.005","article-title":"Cardiovascular disease in India: A 360\u2009degree overview","volume":"76","author":"A Sreeniwas Kumar","year":"2020","journal-title":"Med J Armed Forces India"},{"key":"pone.0320365.ref024","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.15420\/cfr.2022.06","article-title":"Epidemiology and clinical features of heart failure with preserved ejection fraction","volume":"8","author":"K Teramoto","year":"2022","journal-title":"Card Fail Rev"},{"issue":"19","key":"pone.0320365.ref025","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1093\/eurheartj\/ehs337","article-title":"Predicting survival in heart failure: A risk score based on 39 372 patients from 30 studies","volume":"34","author":"SJ Pocock","year":"2013","journal-title":"Eur Heart J"},{"key":"pone.0320365.ref026","doi-asserted-by":"crossref","first-page":"1153310","DOI":"10.3389\/fcvm.2023.1153310","article-title":"Factors associated with lipid control in outpatients with heart failure","volume":"10","author":"A Jarab","year":"2023","journal-title":"Frontiers in Cardiovascular Medicine"},{"issue":"1","key":"pone.0320365.ref027","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s12944-019-1171-8","article-title":"Mechanisms underlying direct actions of hyperlipidemia on myocardium: an updated review","volume":"19","author":"YS Yao","year":"2020","journal-title":"Lipids Health Dis"},{"issue":"4-5","key":"pone.0320365.ref028","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1159\/000534155","article-title":"Biomarker phenotypes in heart failure with preserved ejection fraction using hierarchical clustering-a pilot study","volume":"32","author":"V Mitic","year":"2023","journal-title":"Med Princ Pract"},{"issue":"4","key":"pone.0320365.ref029","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1620\/tjem.250.233","article-title":"Cardiac remodeling biomarkers as potential circulating markers of left ventricular hypertrophy in heart failure with preserved ejection fraction","volume":"250","author":"VT Mitic","year":"2020","journal-title":"Tohoku J Exp Med"},{"issue":"4","key":"pone.0320365.ref030","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1080\/10408363.2018.1460576","article-title":"Novel heart failure biomarkers: why do we fail to exploit their potential?","volume":"55","author":"A Piek","year":"2018","journal-title":"Crit Rev Clin Lab Sci"},{"issue":"6","key":"pone.0320365.ref031","doi-asserted-by":"crossref","first-page":"308","DOI":"10.14744\/AnatolJCardiol.2023.3297","article-title":"How to use natriuretic peptides in patients with heart failure with non-reduced ejection fraction?","volume":"27","author":"A \u00c7elik","year":"2023","journal-title":"Anatol J Cardiol"},{"issue":"2","key":"pone.0320365.ref032","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1042\/CS20150469","article-title":"The natriuretic peptides system in the pathophysiology of heart failure: from molecular basis to treatment","volume":"130","author":"M Volpe","year":"2016","journal-title":"Clin Sci (Lond)"},{"issue":"23","key":"pone.0320365.ref033","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1136\/heartjnl-2015-307782","article-title":"KorHF Registry. Prognostic value of NT-proBNP in heart failure with preserved versus reduced EF","volume":"101","author":"S Kang","year":"2015","journal-title":"Heart"},{"issue":"8","key":"pone.0320365.ref034","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.3390\/ijms20081820","article-title":"BNP and NT-proBNP as diagnostic biomarkers for cardiac dysfunction in both clinical and forensic medicine","volume":"20","author":"Z Cao","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"10","key":"pone.0320365.ref035","doi-asserted-by":"crossref","first-page":"e009427","DOI":"10.1161\/CIRCHEARTFAILURE.121.009427","article-title":"Reference ranges for NT-proBNP (N-terminal pro-B-type natriuretic peptide) and risk factors for higher NT-proBNP concentrations in a large general population cohort","volume":"15","author":"P Welsh","year":"2022","journal-title":"Circ Heart Fail"},{"issue":"17","key":"pone.0320365.ref036","doi-asserted-by":"crossref","first-page":"e263-421","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: A report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines","volume":"79","author":"P Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"pone.0320365.ref037","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3343\/alm.2023.43.3.225","article-title":"Biomarkers in heart failure: From research to clinical practice","volume":"43","author":"AE Berezin","year":"2023","journal-title":"Ann Lab Med"},{"issue":"17","key":"pone.0320365.ref038","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1016\/j.jacc.2019.08.1039","article-title":"Clinical and prognostic significance of sST2 in heart failure: JACC review topic of the week","volume":"74","author":"A Aimo","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"pone.0320365.ref039","doi-asserted-by":"crossref","first-page":"270","DOI":"10.3390\/jcm8020270","article-title":"Cardiac biomarkers in the emergency department: The role of soluble ST2 (sST2) in acute heart failure and acute coronary syndrome-there is meat on the bone","volume":"8","author":"A Aleksova","year":"2019","journal-title":"J Clin Med"},{"issue":"4","key":"pone.0320365.ref040","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.21037\/apm-20-1046","article-title":"Combined use of high-sensitivity ST2 and NT-proBNP for predicting major adverse cardiovascular events in coronary heart failure","volume":"9","author":"J Bai","year":"2020","journal-title":"Ann Palliat Med"},{"issue":"1","key":"pone.0320365.ref041","doi-asserted-by":"crossref","DOI":"10.1016\/j.hfc.2017.08.009","article-title":"Galectin-3 in heart failure: An update of the last 3 years","volume":"14","author":"C Gehlken","year":"2018","journal-title":"Heart Fail Clin"},{"issue":"2","key":"pone.0320365.ref042","first-page":"129","article-title":"Galectin-3: A novel biomarker for the prognosis of heart failure","volume":"90","author":"HZ Amin","year":"2017","journal-title":"Clujul Med"},{"issue":"17","key":"pone.0320365.ref043","doi-asserted-by":"crossref","first-page":"13111","DOI":"10.3390\/ijms241713111","article-title":"The role of Galectin-3 in heart failure-the diagnostic, prognostic and therapeutic potential-where do we stand?","volume":"24","author":"B Zaborska","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"7","key":"pone.0320365.ref044","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1038\/aps.2018.30","article-title":"miRNAS in cardiovascular diseases: Potential biomarkers, therapeutic targets and challenges","volume":"39","author":"S-S Zhou","year":"2018","journal-title":"Acta Pharmacol Sin"},{"key":"pone.0320365.ref045","doi-asserted-by":"crossref","first-page":"856358","DOI":"10.3389\/fcvm.2022.856358","article-title":"The microrna expression profiling in heart failure: A systematic review and meta-analysis","volume":"9","author":"N-N Shen","year":"2022","journal-title":"Front Cardiovasc Med"},{"issue":"1","key":"pone.0320365.ref046","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1161\/CIRCHEARTFAILURE.111.963637","article-title":"Galectin-3 in ambulatory patients with heart failure: results from the HF-ACTION study","volume":"5","author":"GM Felker","year":"2012","journal-title":"Circ Heart Fail"},{"issue":"16","key":"pone.0320365.ref047","first-page":"e240-327","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: A report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines","volume":"128","author":"American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","year":"2013","journal-title":"Circulation"},{"issue":"2","key":"pone.0320365.ref048","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s10741-021-10105-w","article-title":"Biomarkers for the diagnosis and management of heart failure","volume":"27","author":"V Castiglione","year":"2022","journal-title":"Heart Fail Rev"},{"issue":"1","key":"pone.0320365.ref049","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jacc.2005.08.051","article-title":"Renal function, congestive heart failure, and amino-terminal pro-brain natriuretic peptide measurement: Results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study","volume":"47","author":"S Anwaruddin","year":"2006","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"pone.0320365.ref050","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s00392-010-0125-y","article-title":"Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study","volume":"99","author":"DJA Lok","year":"2010","journal-title":"Clin Res Cardiol"},{"issue":"2","key":"pone.0320365.ref051","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1161\/CIRCHEARTFAILURE.112.000129","article-title":"Prognostic value of changes in galectin-3 levels over time in patients with heart failure: Data from CORONA and COACH","volume":"6","author":"AR van der Velde","year":"2013","journal-title":"Circ Heart Fail"},{"issue":"4","key":"pone.0320365.ref052","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1002\/ehf2.13371","article-title":"Identification of novel circulating microRNAs in advanced heart failure by next-generation sequencing","volume":"8","author":"A Galluzzo","year":"2021","journal-title":"ESC Heart Fail"},{"key":"pone.0320365.ref053","doi-asserted-by":"crossref","first-page":"5139","DOI":"10.12659\/MSM.908840","article-title":"Differential and predictive value of galectin-3 and soluble suppression of tumorigenicity-2 (sst2) in heart failure with preserved ejection fraction","volume":"24","author":"Y Cui","year":"2018","journal-title":"Med Sci Monit"},{"issue":"3","key":"pone.0320365.ref054","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.hlc.2019.02.004","article-title":"BNP-response to acute heart failure treatment identifies high-risk population","volume":"29","author":"AN Patel","year":"2020","journal-title":"Heart Lung Circ"},{"issue":"2","key":"pone.0320365.ref055","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.hfc.2018.12.008","article-title":"Biomarkers and imaging: Complementary or subtractive?","volume":"15","author":"A Salzano","year":"2019","journal-title":"Heart Failure Clinics"},{"issue":"2","key":"pone.0320365.ref056","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.hfc.2021.01.002","article-title":"Biomarkers in Heart Failure: Clinical Insights","volume":"17","author":"A Salzano","year":"2021","journal-title":"Heart Fail Clin"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0320365","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T15:05:59Z","timestamp":1744383959000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0320365"}},"subtitle":[],"editor":[{"given":"Tommaso","family":"Lomonaco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,4,3]]},"references-count":56,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4,3]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0320365","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,3]]}}}